Lv4
570 积分 2024-02-03 加入
Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours
1个月前
已完结
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
7个月前
已完结
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
7个月前
已完结
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
7个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
7个月前
已完结
Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions
7个月前
已完结
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
7个月前
已完结
The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy
7个月前
已完结
Neoadjuvant checkpoint blockade for cancer immunotherapy
7个月前
已完结
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
7个月前
已完结
皖公网安备34019202002308
